Jump Financial’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.13M Buy
+89,386
New +$2.48M 0.03% 628
2025
Q4
Sell
-144,500
Closed -$3.51M 1936
2025
Q3
$3.51M Buy
+144,500
New +$2.87M 0.04% 519
2025
Q1
Sell
-34,498
Closed -$856K 1594
2024
Q4
$856K Sell
34,498
-8,601
-20% -$220K 0.02% 820
2024
Q3
$1.06M Buy
+43,099
New +$1.11M 0.02% 777
2023
Q4
Sell
-32,330
Closed -$778K 1790
2023
Q3
$778K Buy
32,330
+5,105
+19% +$137K 0.03% 796
2023
Q2
$869K Buy
+27,225
New +$884K 0.03% 754
2023
Q1
Sell
-37,463
Closed -$1.47M 1593
2022
Q4
$1.47M Buy
+37,463
New +$1.68M 0.08% 339
2022
Q3
Sell
-61,614
Closed -$2.39M 1597
2022
Q2
$2.39M Buy
61,614
+8,468
+16% +$337K 0.1% 269
2022
Q1
$3.04M Buy
+53,146
New +$3.49M 0.13% 193
2021
Q4
Sell
-19,570
Closed -$1.7M 1382
2021
Q3
$1.7M Buy
+19,570
New +$1.97M 0.12% 185
2021
Q2
Sell
-27,338
Closed -$2.19M 1087
2021
Q1
$2.19M Buy
+27,338
New +$2.6M 0.2% 64

Other funds holding BEAM

Jump Financial's BEAM Position: Q1 2026 in Review

Jump Financial opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 89,386 shares worth $2.13M. The stake represents 0.03% of the portfolio and ranks #628 among its holdings. This is a return to the name: Jump Financial previously reported a position in BEAM as recently as Q3 2025.

Jump Financial first reported a position in BEAM in Q1 2021 and has held it in 11 quarters since. The position peaked at $3.51M in Q3 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Jump Financial held 89,386 shares of Beam Therapeutics worth $2.13M as of Q1 2026.
  • Beam Therapeutics was a new Jump Financial position in Q1 2026.
  • Beam Therapeutics made up 0.03% of Jump Financial's portfolio in Q1 2026, its #628 holding.
  • Jump Financial first reported a position in Beam Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Jump Financial's Beam Therapeutics position peaked at $3.51M in Q3 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.